JP2016512202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512202A5 JP2016512202A5 JP2015561849A JP2015561849A JP2016512202A5 JP 2016512202 A5 JP2016512202 A5 JP 2016512202A5 JP 2015561849 A JP2015561849 A JP 2015561849A JP 2015561849 A JP2015561849 A JP 2015561849A JP 2016512202 A5 JP2016512202 A5 JP 2016512202A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- alkenyl
- alkyl
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 206010016654 Fibrosis Diseases 0.000 claims 9
- 230000004761 fibrosis Effects 0.000 claims 9
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 7
- 230000002500 effect on skin Effects 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 231100000241 scar Toxicity 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 208000028208 end stage renal disease Diseases 0.000 claims 2
- 201000000523 end stage renal failure Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010035653 pneumoconiosis Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000032984 Intraoperative Complications Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 208000010123 anthracosis Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229940125798 integrin inhibitor Drugs 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 0 *c1c(*)c(*)c(*)c(*)c1* Chemical compound *c1c(*)c(*)c(*)c(*)c1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798269P | 2013-03-15 | 2013-03-15 | |
| US61/798,269 | 2013-03-15 | ||
| PCT/CA2014/000236 WO2014138906A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds and related method for the treatment of fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512202A JP2016512202A (ja) | 2016-04-25 |
| JP2016512202A5 true JP2016512202A5 (enExample) | 2017-04-13 |
| JP6448562B2 JP6448562B2 (ja) | 2019-01-09 |
Family
ID=51535669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561849A Expired - Fee Related JP6448562B2 (ja) | 2013-03-15 | 2014-03-14 | 線維症を治療するための置換芳香族化合物及び関連方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10023518B2 (enExample) |
| EP (1) | EP2970089B1 (enExample) |
| JP (1) | JP6448562B2 (enExample) |
| KR (1) | KR102196721B1 (enExample) |
| CN (2) | CN105189438A (enExample) |
| AR (1) | AR095429A1 (enExample) |
| AU (1) | AU2014231648B2 (enExample) |
| BR (1) | BR112015022008A2 (enExample) |
| CA (1) | CA2905621C (enExample) |
| CL (1) | CL2015002535A1 (enExample) |
| DK (1) | DK2970089T3 (enExample) |
| EA (1) | EA030651B1 (enExample) |
| ES (1) | ES2741439T3 (enExample) |
| IL (1) | IL241178B (enExample) |
| MX (1) | MX379424B (enExample) |
| MY (1) | MY180305A (enExample) |
| NZ (1) | NZ712797A (enExample) |
| PH (1) | PH12015502011B1 (enExample) |
| PL (1) | PL2970089T3 (enExample) |
| PT (1) | PT2970089T (enExample) |
| SG (1) | SG11201507408XA (enExample) |
| TW (1) | TWI689490B (enExample) |
| UY (1) | UY35402A (enExample) |
| WO (1) | WO2014138906A1 (enExample) |
| ZA (1) | ZA201507061B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CN105658653A (zh) | 2013-08-23 | 2016-06-08 | 因赛特公司 | 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CA2963354A1 (en) * | 2014-10-10 | 2016-04-14 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis |
| PL3203998T3 (pl) * | 2014-10-10 | 2021-09-27 | Liminal Biosciences Limited | Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia cukrzycy |
| TWI723967B (zh) * | 2014-11-12 | 2021-04-11 | 英商邊緣生物科技有限公司 | 用於組織自修復及再生之經取代芳族化合物及醫藥組合物 |
| JP6716598B2 (ja) * | 2015-03-18 | 2020-07-01 | ヴェクタス バイオシステムズ リミテッド | 腎臓及び／又は肝臓疾患を治療するための組成物 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| US10463645B2 (en) * | 2016-05-19 | 2019-11-05 | Everfront Biotech Inc. | Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis |
| WO2018107690A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| KR102126389B1 (ko) * | 2018-09-14 | 2020-06-25 | 셀라이온바이오메드 주식회사 | 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물 |
| SG11202103011YA (en) | 2018-10-11 | 2021-04-29 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| MX2023004137A (es) * | 2020-10-06 | 2023-06-22 | Pharmaceutique Ingenew Inc | Compuestos aromaticos sustituidos y composiciones farmaceuticas de los mismos. |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183519A1 (en) * | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| WO2007140189A2 (en) * | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted carboxylic acid compounds |
| ES2657484T3 (es) * | 2007-02-08 | 2018-03-05 | Emisphere Technologies, Inc. | Agentes de administración de ácido fenilalquilcarboxílico |
| PT2427416E (pt) * | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
| KR20120090011A (ko) * | 2009-05-04 | 2012-08-16 | 프로메틱 바이오사이언시즈 인코포레이티드 | 3-펜틸페닐아세트산의 염 및 이의 약학적 용도 |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
-
2014
- 2014-03-12 TW TW103108723A patent/TWI689490B/zh not_active IP Right Cessation
- 2014-03-13 AR ARP140100973A patent/AR095429A1/es unknown
- 2014-03-13 UY UY0001035402A patent/UY35402A/es not_active Application Discontinuation
- 2014-03-14 MX MX2015011878A patent/MX379424B/es unknown
- 2014-03-14 DK DK14764458.7T patent/DK2970089T3/da active
- 2014-03-14 CN CN201480013578.9A patent/CN105189438A/zh active Pending
- 2014-03-14 CA CA2905621A patent/CA2905621C/en active Active
- 2014-03-14 AU AU2014231648A patent/AU2014231648B2/en not_active Ceased
- 2014-03-14 EP EP14764458.7A patent/EP2970089B1/en active Active
- 2014-03-14 PL PL14764458T patent/PL2970089T3/pl unknown
- 2014-03-14 NZ NZ712797A patent/NZ712797A/en not_active IP Right Cessation
- 2014-03-14 US US14/776,328 patent/US10023518B2/en active Active
- 2014-03-14 KR KR1020157029293A patent/KR102196721B1/ko not_active Expired - Fee Related
- 2014-03-14 PT PT14764458T patent/PT2970089T/pt unknown
- 2014-03-14 JP JP2015561849A patent/JP6448562B2/ja not_active Expired - Fee Related
- 2014-03-14 SG SG11201507408XA patent/SG11201507408XA/en unknown
- 2014-03-14 ES ES14764458T patent/ES2741439T3/es active Active
- 2014-03-14 MY MYPI2015002293A patent/MY180305A/en unknown
- 2014-03-14 BR BR112015022008-8A patent/BR112015022008A2/pt active Search and Examination
- 2014-03-14 EA EA201591775A patent/EA030651B1/ru not_active IP Right Cessation
- 2014-03-14 WO PCT/CA2014/000236 patent/WO2014138906A1/en not_active Ceased
- 2014-03-14 CN CN201910355464.7A patent/CN110105200B/zh not_active Expired - Fee Related
-
2015
- 2015-09-03 IL IL241178A patent/IL241178B/en active IP Right Grant
- 2015-09-09 CL CL2015002535A patent/CL2015002535A1/es unknown
- 2015-09-09 PH PH12015502011A patent/PH12015502011B1/en unknown
- 2015-09-22 ZA ZA2015/07061A patent/ZA201507061B/en unknown
-
2018
- 2018-04-04 US US15/945,408 patent/US10550066B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 US US16/780,316 patent/US11524930B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512202A5 (enExample) | ||
| JP2016510769A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| CN110105200B (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| JP2012525393A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| AU2021285747A8 (en) | LPA receptor antagonists and uses thereof | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| JP2017523219A5 (enExample) | ||
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2018518537A5 (enExample) | ||
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| JP2013507415A5 (enExample) | ||
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2017523225A5 (enExample) | ||
| JP2010530376A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| MX2021003253A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| RU2013147739A (ru) | Фармацевтическая композиция | |
| JP2015508068A5 (enExample) | ||
| JP2018538306A5 (enExample) |